Teva Pharmaceutical Industries (NYSE:TEVA) has been assigned a $12.00 target price by equities researchers at HSBC in a report released on Tuesday, February 5th. The firm presently has a “sell” rating on the stock. HSBC’s target price points to a potential downside of 29.74% from the company’s current price.
Several other research firms have also recently issued reports on TEVA. Zacks Investment Research raised Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $24.00 price target for the company in a research note on Monday, December 3rd. Maxim Group restated a “hold” rating on shares of Teva Pharmaceutical Industries in a research note on Thursday, November 1st. Oppenheimer reaffirmed a “hold” rating on shares of Teva Pharmaceutical Industries in a research report on Wednesday, November 7th. Royal Bank of Canada set a $22.00 target price on Teva Pharmaceutical Industries and gave the company a “hold” rating in a research report on Friday, November 2nd. Finally, Wells Fargo & Co reaffirmed a “hold” rating on shares of Teva Pharmaceutical Industries in a research report on Friday, November 2nd. Three equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, five have given a buy rating and one has given a strong buy rating to the company. Teva Pharmaceutical Industries has an average rating of “Hold” and a consensus target price of $21.75.
TEVA traded up $0.25 during trading on Tuesday, hitting $17.08. The company’s stock had a trading volume of 6,540,702 shares, compared to its average volume of 10,896,610. The company has a current ratio of 0.96, a quick ratio of 0.61 and a debt-to-equity ratio of 1.69. Teva Pharmaceutical Industries has a one year low of $14.59 and a one year high of $25.96. The company has a market capitalization of $17.54 billion, a PE ratio of 6.10, a PEG ratio of 3.27 and a beta of 1.46.
Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Wednesday, February 13th. The company reported $0.53 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.53. The company had revenue of $4.56 billion during the quarter, compared to analyst estimates of $4.52 billion. Teva Pharmaceutical Industries had a negative net margin of 11.40% and a positive return on equity of 18.57%. The firm’s revenue for the quarter was down 15.5% on a year-over-year basis. During the same quarter last year, the business posted $0.93 EPS. Equities analysts forecast that Teva Pharmaceutical Industries will post 2.33 earnings per share for the current fiscal year.
In related news, VP Hafrun Fridriksdottir sold 1,643 shares of the company’s stock in a transaction on Wednesday, January 2nd. The shares were sold at an average price of $15.70, for a total value of $25,795.10. Following the completion of the transaction, the vice president now directly owns 13,469 shares in the company, valued at $211,463.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Notaristefani Carlo De sold 5,041 shares of the company’s stock in a transaction on Wednesday, February 13th. The stock was sold at an average price of $17.88, for a total transaction of $90,133.08. Following the completion of the transaction, the vice president now owns 17,162 shares of the company’s stock, valued at $306,856.56. The disclosure for this sale can be found here. Company insiders own 0.43% of the company’s stock.
Large investors have recently made changes to their positions in the stock. Northstar Group Inc. raised its holdings in Teva Pharmaceutical Industries by 34.9% during the fourth quarter. Northstar Group Inc. now owns 15,468 shares of the company’s stock worth $239,000 after purchasing an additional 4,000 shares in the last quarter. Cacti Asset Management LLC grew its holdings in Teva Pharmaceutical Industries by 12.5% in the 4th quarter. Cacti Asset Management LLC now owns 577,904 shares of the company’s stock valued at $8,911,000 after buying an additional 64,180 shares during the last quarter. Virtu Financial LLC grew its holdings in shares of Teva Pharmaceutical Industries by 665.0% during the 3rd quarter. Virtu Financial LLC now owns 271,537 shares of the company’s stock worth $5,849,000 after purchasing an additional 236,044 shares in the last quarter. Handelsbanken Fonder AB bought a new position in shares of Teva Pharmaceutical Industries during the 3rd quarter worth approximately $485,000. Finally, AGF Investments America Inc. lifted its position in shares of Teva Pharmaceutical Industries by 2.5% during the 4th quarter. AGF Investments America Inc. now owns 60,321 shares of the company’s stock worth $930,000 after buying an additional 1,458 shares during the period. Institutional investors own 61.97% of the company’s stock.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
Featured Article: Dollar Cost Averaging
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.